Evaluating a new test for diagnosing nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study assesses the diagnostic performance of a novel Epstein-Barr virus (EBV) C promoter methylation detection kit for nasopharyngeal carcinoma. Participants will undergo various diagnostic tests, including VCA-IgA, EBNA1-IgA, and EBV-DNA assays, along with nasopharyngeal swabs to analyze EBV C promoter methylation. A confirmatory biopsy will be performed on all patients to establish a definitive diagnosis, aiming to evaluate the kit's effectiveness in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants who meet the following Article 1 and also meet one of Articles 2 to 6 can be enrolled:

* Understand, sign, and date the informed consent document to participate in the study
* Display one or more symptoms or signs indicative of nasopharyngeal carcinoma
* Test positive for EBV antibodies or EBV DNA
* Be diagnosed with other head and neck carcinomas
* Be diagnosed with malignancies associated with EBV infection
* Require differential diagnosis from nasopharyngeal carcinoma during endoscopic or other imaging examinations
* Fulfill any additional conditions deemed appropriate by the investigator for inclusion in this study

Exclusion Criteria:

* Have been diagnosed with nasopharyngeal carcinoma and have undergone treatment
* Experience relapse or metastasis of nasopharyngeal carcinoma following treatment
* Have unsuccessful nasopharyngeal swab collections
* Present any other conditions considered by the investigator as unsuitable for participation in this trial

Where it's running

• Fujian Cancer Hospital
  Fuzhou, Fujian, China Recruiting
• Sun Yat-Sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting
• ZhongShan City People's Hospital
  Zhongshan, Guangdong, China Recruiting
• The First Affiliated Hospital of Guangxi Medical University
  Nanning, Guangxi, China Recruiting
• Wuzhou Red Cross Hospital
  Wuzhou, Guangxi, China Recruiting

Study contacts

• Principal investigator: Zhen-Zhou Xiao — Fujian Cancer Hospital
• Study coordinator: Hai-Qiang Mai
• Email: maihq@sysucc.org.cn
• Phone: +86-020-87343380

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Induction and maintenance with MRG003, Tislelizumab, and Capecitabine for locally recurrent nasopharyngeal cancer

  This study tests a treatment combo of MRG003 and a PD-1 blocker first, then continues with Capecitabine plus the PD-1 blocker to see if it helps patients with locally recurrent NPC.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07331428

• Lower-dose (40.2 Gy) versus standard-dose (49.2 Gy) radiotherapy to low‑risk areas for chemosensitive Stage II nasopharyngeal cancer

  This trial will try a lower radiotherapy dose (40.2 Gy) instead of the standard 49.2 Gy for people with stage II nasopharyngeal cancer who had a strong response to induction chemo and have undetectable EBV DNA.

  Recruiting at 15 sites Phase 3 Sun Yat-sen University · Hefei, Anhui and 14 other locations · NCT07328854

• Screening for early nasopharyngeal (nose) cancer

  This project tests whether blood and saliva markers can find nasopharyngeal cancer early in adults aged 35 to 60 who are at higher risk because of ethnicity or family history.

  Recruiting at 2 sites National University Hospital, Singapore · Singapore and 1 other locations · NCT07019870

• Proton versus photon radiation for nasopharyngeal cancer

  This trial will test whether proton radiation works at least as well as standard photon radiation for adults newly diagnosed with nasopharyngeal cancer that has not spread.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan · NCT07000643

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.